ALS Center Karolinska

Karolinska Institutet

The Karolinska ALS Clinical Research Group is part of a tertiary center for ALS that provides multidisciplinary care to ALS patients from the Greater Stockholm region. The clinical team also offers second opinions for ALS patients coming from all Sweden and from abroad. ALS patients are seen in our two clinics, located both at Huddinge and Solna Hospitals, which belong to the Karolinska University Hospitals.

Karolinska Institutet

The research activities of the group are linked to the Karolinska Institute and cover epidemiological research, risk and prognosis studies, quality of life, and wet and dry biomarkers investigation. The Karolinska ALS Clinical Research Group also initiated the National ALS/MND Registry that collects data on ALS/MND patients from all Sweden, and the ALS Risc project that is an epidemiological study gathering data and samples from the greater Stockholm region. This work goes hand in hand with the ALS biobank in place, which allows for samples to be stored and used for research.

We are currently running several ALS clinical trials, in two specialized units. They are located at the Huddinge Hospital (Phase 1) and at the S-ASC Unit (Phase 2 and 3) in the center of Stockholm.

To find out more about the activities of the Karolinska ALS Clinical Research Group, please go to our website: ALS Clinical Research Group | Karolinska Institutet (

Our core team in composed of:

  • Caroline Ingre, head of the Karolinska ALS Clinical Research Group, head of the National ALS7MND Registry in Sweden, TRICALS board member
  • Ulf Kläppe, neurologist and PhD student
  • Sanharib Chamoun, neurologist and PhD student
  • Sebastian Thams, neurologist
  • Linn Öijerstedt, neurologist and post-doctoral researcher
  • Stefan Sennfält, neurologist and post-doctoral researcher
  • Juliette Foucher, PhD student and clinical trial coordinator, Nordic Patient Liaison for TRICALS
  • Karolina Palmbäck, research nurse
  • Jenny Hellqvist, assistant nurse
  • Oskar Holmdahl, research nurse
Karolinska Universitetssjukhuset Huddinge, 18146, Stockholm, Sweden

Our Specialists

Caroline Ingre

Neurologist and Researcher

Dr. Caroline Ingre is a specialist in neuromuscular disease, and has been […]

Caroline Ingre
Current trials
Phase ii


Industry trial
In this study we investigate the safety, tolerability, pharmacodynamics markers and pharmacokinetics (how a drug is absorbed and excreted) of AP-101 in patients with familial and sporadic amyotrophic lateral sclerosis (ALS). Currently, we are only looking for patients with familial ALS (caused by a SOD1 gene mutation) to participate in the study. This study is sponsored by AL-S Pharma.
Read more
Phase iii


Industry trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035' for the treatment of ALS.
Read more
Phase iii

ADORE trial

Industry trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Read more